Bladder-sparing therapy for HER2+ muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs—an antibody-drug conjugate (Disitamab Vedotin) and an immunotherapy (Toripalimab)—given for different lengths of time to treat muscle-invasive bladder cancer. The goal is to preserve the bladder while controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your bladder cancer must be muscle-invasive and not have spread outside the bladder (stage cT2-4aN0M0).
- Your tumor must show some HER2 protein (at least 1+ on a test).
- You cannot have had prior chemotherapy or other drugs for bladder cancer.
- You must be in good enough health to do daily activities (ECOG 0 or 1).
- You cannot have active autoimmune or inflammatory disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (disitamab vedotin) combined with immunotherapy against the standard chemotherapy-immunotherapy combination for muscle-invasive bladder cancer that expresses HER2 protein. The goal is to see if the new approach works better and is safer for patients before bladder removal surgery.
This trial studies a combination of two drugs for bladder cancer that has not spread beyond the bladder. It aims to help patients who want to avoid bladder removal surgery, potentially preserving their bladder.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial tests a combination of immunotherapy (toripalimab), a targeted antibody-drug (RC48-ADC), and radiation to try to save the bladder in people with HER2-positive muscle-invasive bladder cancer. The goal is to see if this approach can shrink or eliminate the cancer without needing surgery to remove the bladder.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs: vedisertib (a targeted therapy that attacks cancer cells with a certain protein) and toripalimab (an immunotherapy that helps your immune system fight cancer). The goal is to treat your bladder cancer while avoiding removal of the bladder.
Hear when a new Urology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.